Mylan (NASDAQ:MYL)‘s stock had its “buy” rating restated by analysts at Citigroup in a report released on Thursday, January 4th, Marketbeat Ratings reports. They presently have a $58.00 target price on the stock, up from their prior target price of $48.00. Citigroup’s price objective suggests a potential upside of 24.17% from the company’s current price.
Several other equities research analysts have also weighed in on MYL. Leerink Swann began coverage on shares of Mylan in a research note on Tuesday, January 2nd. They set a “market perform” rating and a $44.00 price objective on the stock. Cantor Fitzgerald set a $41.00 price objective on shares of Mylan and gave the company a “hold” rating in a report on Tuesday, December 26th. BidaskClub upgraded shares of Mylan from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 19th. Guggenheim began coverage on shares of Mylan in a report on Tuesday, December 12th. They set a “buy” rating and a $59.00 target price for the company. Finally, UBS Group set a $46.00 price target on shares of Mylan and gave the company a “buy” rating in a research report on Monday, December 4th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $43.64.
Shares of Mylan (NASDAQ MYL) traded up $2.32 on Thursday, reaching $46.71. The company’s stock had a trading volume of 8,970,600 shares, compared to its average volume of 6,721,550. Mylan has a 52 week low of $29.39 and a 52 week high of $46.76. The firm has a market cap of $25,060.00, a P/E ratio of 28.14, a PEG ratio of 1.41 and a beta of 1.38. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95.
Mylan (NASDAQ:MYL) last announced its quarterly earnings results on Monday, November 6th. The company reported $1.10 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The business had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $3.09 billion. During the same period last year, the company posted $1.38 earnings per share. The firm’s revenue for the quarter was down 2.3% on a year-over-year basis. research analysts anticipate that Mylan will post 4.56 earnings per share for the current year.
In other news, CEO Heather M. Bresch sold 75,000 shares of the business’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total value of $3,375,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.69% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Hexavest Inc. increased its holdings in shares of Mylan by 1.7% in the fourth quarter. Hexavest Inc. now owns 1,435,251 shares of the company’s stock valued at $60,725,000 after purchasing an additional 23,353 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Mylan by 170.9% in the fourth quarter. Nisa Investment Advisors LLC now owns 137,725 shares of the company’s stock valued at $5,827,000 after purchasing an additional 86,888 shares during the last quarter. Greenlight Capital Inc. increased its holdings in shares of Mylan by 0.4% in the third quarter. Greenlight Capital Inc. now owns 10,744,307 shares of the company’s stock valued at $337,048,000 after purchasing an additional 42,600 shares during the last quarter. Wealthsource Partners LLC increased its holdings in shares of Mylan by 57.6% in the third quarter. Wealthsource Partners LLC now owns 14,705 shares of the company’s stock valued at $461,000 after purchasing an additional 5,375 shares during the last quarter. Finally, Americafirst Capital Management LLC acquired a new position in shares of Mylan in the third quarter valued at $471,000. 74.90% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/01/12/mylan-myl-receives-buy-rating-from-citigroup.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.